Market Trends of Global G-Protein Coupled Receptors (GPCR) Industry
Oncology by Application Segment is Estimated to Hold a Significant Share of the Market Over Forecast Period
- According to a November 2021 article published by PubMed Central, there are more than 700 genes that make up the G-protein-coupled receptors (GPCRs), which constitute the largest family of cell surface signaling receptors in the human genome. These receptors play a vital role in various physiological functions, including sensory modulations and hormonal responses. Recent research has shown that GPCR signaling affects different aspects of cancer biology, such as invasion, migration, and vascular remodeling. GPCRs are important in many types of cancer, contributing to cancer proliferation, angiogenesis, invasion, and metastasis.
- Another article published in the Journal of Current Opinion in Endocrine and Metabolic Research in February 2021 states that GPCRs regulate cellular functions that mediate cell survival, tumor progression, and metastasis, making them significant contributors to oncogenesis. Hence, the development of GPCR-targeted drugs is a promising novel therapeutic strategy for treating various types of cancers.
- To improve our understanding of tumorigenesis and oncogenesis and to help develop novel anti-cancer therapies, it is crucial to discern how G protein-coupled receptor kinases (GRKs) regulate GPCR activity in cancer cells. As GPCR signaling plays a significant role in tumor growth and metastasis, the oncology segment is expected to show growth over the forecast period. Targeting GPCRs and their signaling circuits for the new era of precision medicine and cancer immunotherapies is the focus of current and future research.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share of the Market Over the Forecast Period
- North America is expected to experience significant growth during the forecast period, driven by the economically advanced and technologically developed countries of the United States, Canada, and Mexico. Increasing government investment in the biotechnology and biopharmaceutical sector is also contributing to the growth of the studied market in the region.
- The burden of chronic diseases, particularly in the cardiovascular and cancer applications, is increasing demand for advanced treatments and therapies, further supporting market growth in North America. In 2022, the American Cancer Society estimated that there would be 1.9 million new cancer cases and 609,360 cancer deaths in the United States alone. Similarly, the Canadian Cancer Statistics 2021 reported that approximately 2 in 5 Canadians will be diagnosed with cancer in their lifetime, and 1 in 4 will die from cancer. In 2021, an estimated 229,200 Canadians were diagnosed with cancer, and 84,600 died from cancer.
- The burden of cancer is driving emerging research and findings for advanced therapies, such as the use of designer receptors exclusively activated by a designer drug (DREADDs), which may support the clinical exploration of novel classes of drugs for the treatment of cancer patients and survivors. Additionally, research from Columbia.
Get Analysis on Important Geographic Markets
Download PDF
